Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neuroendocrine Tumors 1 Neoplasms 1 Malignant Solid Tumour 1 Leukemia, Myeloid, Acute 1 Kidney Neoplasms 1 Glioblastoma 1 Castrate-resistant Prostate Cancer 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

pembrolizumab 37 Gemcitabine 29 Nivolumab 20 Cisplatin 19 atezolizumab 15 avelumab 14 Docetaxel 13 enfortumab vedotin 10 Carboplatin 10 durvalumab 9 Magnetic Resonance Spectroscopy 9 Ipilimumab 8 Paclitaxel 7 Pemetrexed 6 toripalimab 5 cabozantinib 5 Fluorodeoxyglucose F18 5 sacituzumab govitecan 4 cabazitaxel 4 Taxes 4 vinflunine 3 tremelimumab 3 pemigatinib 3 X-Rays 3 Standard of Care 3 Specimen Handling 3 Radiotherapy 3 Mitomycin 3 Immunotherapy 3 Immunoglobulin G 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinoma, Transitional Cell × dactolisib × Clear all

NCT01856101 2019-04-10

BEZ235

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 2 Terminated

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡